FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4232049379> ?p ?o ?g. }

• W4232049379 endingPage "182" @default.
• W4232049379 startingPage "175" @default.
• W4232049379 abstract "The proteolytic breakdown product corresponding to the extracellular domain (ECD) of the HER-2/neu oncoprotein p185 is found in the circulation of healthy individuals and patients having cancers of epithelial origin. For the current evaluation we sought to determine the analytical performance as well as the clinical utility of the newly developed ADVIA Centaur HER-2/neu assay (Bayer HealthCare LLC, Diagnostics Division, Tarrytown, NY, USA) in monitoring patients with metastatic breast cancer during the course of disease and treatment and to compare the obtained results with those of CA 15-3.The analytical performance (including precision, normal range, interfering substances, minimum detectable concentration, dilution recovery, spiking recovery and high-dose hook effect) were determined. HER-2/neu and CA 15-3 values were measured in retrospective samples obtained from 59 patients with metastatic breast cancer undergoing treatment over a 6-12 month period. Serial changes in serum HER-2/neu and CA 15-3 were correlated with changes in clinical status on a visit-to-visit basis. For each pair of serial measurements, changes of equal to or greater than, or less than 15% for HER-2/neu and 21% for CA 15-3 were considered to indicate progression or lack of progression, respectively.The ADVIA Centaur HER-2/neu assay demonstrated within-run imprecision and total imprecision ranging from 3.0-5.6% and from 3.2-5.7%, respectively. The upper limit of normal was 15.2 ng/mL (90% CI: 14.2-17.0 ng/mL). No significant interference (<5%) was seen with bilirubins, hemoglobin, triglycerides and cholesterol or therapeutic drugs commonly present in the sera of breast cancer patients. The minimum detectable concentration (analytical sensitivity) was found to be 0.5 ng/mL. The patient population in the clinical study included breast cancer patients who responded to therapy (stable, partial or complete response) or had disease progression. HER-2/neu levels showed a concordance of 78.1% (82/105 restaging time points) with the clinical course of disease, whereas CA 15-3 levels showed a concordance of 76.2% (80/105 restaging time points). The concordance with clinical status increased to 85.7% (90/105 restaging time points) when both results were used in combination as a series test.The ADVIA Centaur HER-2/neu assay provides excellent analytical performance for serial testing of serum HER-2/neu levels. The clinical data demonstrate the usefulness of serum HER-2/neu in monitoring metastatic breast cancer patients during treatment. Furthermore, the results indicate that serum HER-2/neu and CA 15-3 may be useful in identifying disease progression or therapeutic response in different subgroups of women with metastatic breast cancer." @default.
• W4232049379 created "2022-05-12" @default.
• W4232049379 creator A5035775338 @default.
• W4232049379 creator A5049671183 @default.
• W4232049379 creator A5070382757 @default.
• W4232049379 creator A5081716847 @default.
• W4232049379 creator A5084237231 @default.
• W4232049379 date "2004-07-01" @default.
• W4232049379 modified "2023-09-27" @default.
• W4232049379 title "ADVIA Centaur® Her-2/Neu Shows Value in Monitoring Patients with Metastatic Breast Cancer" @default.
• W4232049379 cites W1922272927 @default.
• W4232049379 cites W1976090068 @default.
• W4232049379 cites W1979443682 @default.
• W4232049379 cites W2003592884 @default.
• W4232049379 cites W2004755792 @default.
• W4232049379 cites W2028387622 @default.
• W4232049379 cites W2038209899 @default.
• W4232049379 cites W2039359329 @default.
• W4232049379 cites W2077778212 @default.
• W4232049379 cites W2084928785 @default.
• W4232049379 cites W2121954422 @default.
• W4232049379 cites W2122812256 @default.
• W4232049379 cites W2141393790 @default.
• W4232049379 cites W2146406055 @default.
• W4232049379 cites W2154027407 @default.
• W4232049379 cites W2159363679 @default.
• W4232049379 cites W2263422734 @default.
• W4232049379 cites W2397597031 @default.
• W4232049379 cites W2400705724 @default.
• W4232049379 cites W2418194483 @default.
• W4232049379 cites W2441235659 @default.
• W4232049379 cites W2466611510 @default.
• W4232049379 cites W4252112751 @default.
• W4232049379 doi "https://doi.org/10.1177/172460080401900301" @default.
• W4232049379 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/15503818" @default.
• W4232049379 hasPublicationYear "2004" @default.
• W4232049379 type Work @default.
• W4232049379 citedByCount "12" @default.
• W4232049379 countsByYear W42320493792013 @default.
• W4232049379 countsByYear W42320493792015 @default.
• W4232049379 countsByYear W42320493792018 @default.
• W4232049379 countsByYear W42320493792020 @default.
• W4232049379 countsByYear W42320493792023 @default.
• W4232049379 crossrefType "journal-article" @default.
• W4232049379 hasAuthorship W4232049379A5035775338 @default.
• W4232049379 hasAuthorship W4232049379A5049671183 @default.
• W4232049379 hasAuthorship W4232049379A5070382757 @default.
• W4232049379 hasAuthorship W4232049379A5081716847 @default.
• W4232049379 hasAuthorship W4232049379A5084237231 @default.
• W4232049379 hasConcept C121608353 @default.
• W4232049379 hasConcept C126322002 @default.
• W4232049379 hasConcept C126894567 @default.
• W4232049379 hasConcept C143998085 @default.
• W4232049379 hasConcept C2775930923 @default.
• W4232049379 hasConcept C530470458 @default.
• W4232049379 hasConcept C71924100 @default.
• W4232049379 hasConcept C90924648 @default.
• W4232049379 hasConceptScore W4232049379C121608353 @default.
• W4232049379 hasConceptScore W4232049379C126322002 @default.
• W4232049379 hasConceptScore W4232049379C126894567 @default.
• W4232049379 hasConceptScore W4232049379C143998085 @default.
• W4232049379 hasConceptScore W4232049379C2775930923 @default.
• W4232049379 hasConceptScore W4232049379C530470458 @default.
• W4232049379 hasConceptScore W4232049379C71924100 @default.
• W4232049379 hasConceptScore W4232049379C90924648 @default.
• W4232049379 hasIssue "3" @default.
• W4232049379 hasLocation W42320493791 @default.
• W4232049379 hasLocation W42320493792 @default.
• W4232049379 hasOpenAccess W4232049379 @default.
• W4232049379 hasPrimaryLocation W42320493791 @default.
• W4232049379 hasRelatedWork W144521535 @default.
• W4232049379 hasRelatedWork W2023654245 @default.
• W4232049379 hasRelatedWork W2037999876 @default.
• W4232049379 hasRelatedWork W2070780645 @default.
• W4232049379 hasRelatedWork W2224319365 @default.
• W4232049379 hasRelatedWork W2411890706 @default.
• W4232049379 hasRelatedWork W2590924520 @default.
• W4232049379 hasRelatedWork W2979892935 @default.
• W4232049379 hasRelatedWork W3181412252 @default.
• W4232049379 hasRelatedWork W377899687 @default.
• W4232049379 hasVolume "19" @default.
• W4232049379 isParatext "false" @default.
• W4232049379 isRetracted "false" @default.
• W4232049379 workType "article" @default.